Committee Approves Fast 15-Min Infusion in Ph I/II Urosepsis
Filed with ASX · · 3 pages · English
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Completes Cohort Dosing UTI/Urosepsis Rapid Infusion Trial
- Placement and Entitlement Offer
- Opening R&D Address at World AMR Congress
- RECCE Trademark Registered - Vietnam
- Additional Positive Patient Cases - Special Access Scheme
Later from Recce Pharmaceuticals
- Subjects Dosed Over 15 mins in UTI/Urosepsis Clinical Trial
- Canadian Patent Granted for RECCE Anti-Infectives
- Murdoch Children's R327 Efficacy N.gonorrhoeae in-vivo
- RCE Awarded $43.7m AusIndustry Advanced Overseas Finding
- RCE Awarded Further $11.17m Advanced Overseas Finding
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals